Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2022 | Story Andrè Damons | Photo Andrè Damons
Prof Motlalepula Matsabisa
This week, Prof Motlalepula Matsabisa, will give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

Prof Motlalepula Matsabisa, Director of Pharmacology at the University of the Free State (UFS), has been invited to give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

While in New York, Prof Matsabisa will also meet with officials from the Wellcome Trust – a global charitable foundation – where he will present a strong and compelling motivation for the Wellcome Trust to invest in traditional medicines. Says Prof Matsabisa: “I will deliver a compelling message for investment to be made in scientific research and development around traditional medicines. This development will be piloted in a hub-and-spoke model based on the African economic blocks, with the hub being in South Africa. The returns on the investment put in this initiative will be massive for the African continent, both socially and economically, and I believe it will lead to self-sustainability and Africa being a supplier of innovations based on the science of traditional medicines.” 

SSUNGA77 is organised by Intelligence in Science and will take place from 13 to 30 September 2022. It will bring together thought leaders, scientists, technologists, innovators, policy makers, decision makers, regulators, financiers, philanthropists, journalists and editors, and community leaders to increase health science and citizen collaboration across a broad spectrum of themes, including ICT, nutrition, agriculture, health, IKS, and the environment.

Prof Matsabisa, an expert in African traditional medicine (ATM) and Chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19 (REACT), is also the convener of this session, following his successful proposal for such a session. The session will take place in person on 20 September at the UN headquarters in New York. It is an official side event of the UN General Assembly’s 77th anniversary and will be co-sponsored by the permanent missions of Ireland, Spain, South Africa, Brazil, and Bangladesh to the UN.

His message at Science Summit

“At the end of the summit, we are to make recommendations to the UN, EU, and AU on IKS and health developmental matters. This is exciting and nerve-wracking for me, but I will remain calm knowing that I have a message to deliver to the highest global decision-making body. There can be nothing greater than presenting my talk and proposals for consideration to such a body.” 

“I will convey three simple messages, namely the importance of traditional medicines in contributing to universal health coverage, the need for Africa – through the heads of state and governments – to take seriously the local manufacturing of traditional medicines for industrialisation, economic emancipation, and responding to poverty and inequality. The third message is the need for sustained and adequate financial support by African ministries of health for the development, commercialisation, and market access to quality and well-researched, safe, and effective traditional medicines in order to contribute to priority diseases as well as responding to pandemics,” says Prof Matsabisa. 

According to him, this address at SSUNGA77 is a chance to correctly position the story on IKS with arguments based on good scientific evidence. “It means we are getting much closer to the institutionalisation and formal economic contribution of IKS to health, and that the African IKS health system is getting international recognition and acceptance,” he says.
Prof Matsabisa says he hopes the message will emerge clearly from his talk that Africa has the resources for raw materials and that the science, as well as the infrastructure, exists to develop IKS and to contribute to new health products. The spin-off is the industrialisation, job creation, and wealth generation that Africa can offer to the rest of the world.

Overall information on the summit is available here

News Archive

UFS research on yeast nanorobotics
2006-05-09

Ten members from the University of the Free State's (UFS) Lipid Biotechnology Research Group in the Department of Microbial, Biochemical and Food Biotechnology will be presenting their research  on yeast nanorobotics (nanotechnology) at three international conferences in Europe during May and June 2006.

 

It is one of the biggest group of students from the department to present their research overseas.  

The conferences to be attended include the 2nd International Conference on Non Mammalian Eicosanoids, Bioactive Lipids and Plant Oxylipins held in Berlin, Germany; the 3rd European Conference on Computational Mechanics (ECCM-2006) held in Lisbon, Portugal and the 25th International Specialised Symposium on Yeasts (ISSY 2006) held in Helsinki, Finland.  The UFS Lipid Biotechnology Group is also co-organising the conference in Berlin.

The group members are in front from the left Ms Chantel Swart (M Sc student), Ms Ntsoaki Leeuw (M Sc student) and Ms Monique Goldblatt (M Sc student).
Middle from the left Mr Olihile Sebolai (Ph D student and recipient of the Free State Premier Excellence Award), Ms Ané van Heerden (M Sc student) and Dr Catrine Strauss (post-doctoral student).
At the back are from the left Mr Desmond Ncango (M Sc), Dr Carlien Pohl (Senior Researcher), Prof Pieter van Wyk (Head: UFS Center for Confocal and Electron Microscopy) and Prof Lodewyk Kock (Head: UFS Lipid Biotechnology Group).
Photo: Stephen Collett

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept